Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Dlin-MC3-DMA: Benchmark Ionizable Cationic Liposome for L...

    2026-01-27

    Dlin-MC3-DMA: Benchmark Ionizable Cationic Liposome for Lipid Nanoparticle siRNA Delivery

    Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid enabling efficient siRNA and mRNA delivery via lipid nanoparticles (LNPs) (Wang et al., 2022). It achieves endosomal escape by acquiring a positive charge at acidic pH while remaining neutral at physiological pH, reducing toxicity (Fig. 1b). Dlin-MC3-DMA exhibits approximately 1000-fold greater hepatic gene silencing potency than its precursor DLin-DMA, with ED50 values of 0.005 mg/kg in mice (Table 2). Machine learning and molecular modeling confirm its superior LNP formulation performance for mRNA vaccines (Results). APExBIO supplies Dlin-MC3-DMA as a research-grade product (SKU A8791), optimized for reproducibility and stability (product page).

    Biological Rationale

    Dlin-MC3-DMA is a synthetic ionizable cationic lipid engineered for nucleic acid delivery. Its structure, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, enables pH-dependent charge switching. This feature is crucial for mediating endosomal escape of encapsulated siRNA or mRNA without causing significant cytotoxicity at physiological pH (Section 3.1). LNPs formulated with Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG provide a robust platform for gene silencing and mRNA-based therapeutics. The compound is insoluble in water and DMSO, but highly soluble in ethanol (≥152.6 mg/mL), facilitating formulation steps (APExBIO).

    Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

    At acidic pH (such as within endosomes), Dlin-MC3-DMA becomes protonated, acquiring a positive charge that promotes interaction with negatively charged endosomal membranes. This interaction destabilizes the endosomal barrier, facilitating nucleic acid cargo escape into the cytoplasm (Fig. 2). At physiological pH (7.4), Dlin-MC3-DMA is largely neutral, minimizing off-target toxicity and nonspecific interactions (Discussion). The molecule's unique structure enables efficient encapsulation and release of siRNA or mRNA (Results).

    Evidence & Benchmarks

    • Dlin-MC3-DMA-based LNPs enable potent hepatic gene silencing with ED50 of 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates (Table 2, DOI).
    • Machine learning models (LightGBM) predict and confirm Dlin-MC3-DMA as superior to SM-102 for mRNA vaccine LNPs in mouse experiments (DOI).
    • Molecular modeling demonstrates stable LNP formation with Dlin-MC3-DMA, facilitating efficient mRNA delivery (DOI).
    • Dlin-MC3-DMA remains neutral at physiological pH, reducing systemic toxicity compared to permanently charged cationic lipids (DOI).
    • High solubility in ethanol (≥152.6 mg/mL) enables reproducible formulation for high-throughput screening (APExBIO).

    Applications, Limits & Misconceptions

    Dlin-MC3-DMA is widely applied in lipid nanoparticle-mediated gene silencing, mRNA vaccine formulation, and cancer immunochemotherapy. Its efficacy spans both hepatic and extrahepatic tissues, with particular validation in liver-targeted applications (Results). Predictive modeling using Dlin-MC3-DMA optimizes LNP composition in silico, accelerating development cycles (contrast: this article details predictive modeling, here we focus on validated benchmarks). Recent reports extend its use to immunomodulatory and microglial targeting contexts, broadening its relevance beyond hepatic gene silencing (contrast: this article provides primary benchmarks and workflow data).

    Common Pitfalls or Misconceptions

    • Dlin-MC3-DMA is not effective as a naked (non-formulated) transfection reagent; it requires LNP incorporation for activity.
    • The compound is insoluble in water and DMSO—attempts to use these solvents for stock or formulation will fail (APExBIO).
    • Its strong in vivo potency is validated primarily for hepatic gene silencing; efficacy in other tissues may require additional optimization or targeting ligands (DOI).
    • Solutions degrade rapidly at room temperature; immediate use after preparation and storage at ≤-20°C are mandatory (APExBIO).
    • Dlin-MC3-DMA is not a direct therapeutic agent but a delivery vehicle component; it has no intrinsic gene silencing or immunomodulatory activity outside of LNP formulations.

    Workflow Integration & Parameters

    Dlin-MC3-DMA is supplied by APExBIO as SKU A8791 in research-grade purity. For LNP formulation, it is typically combined with DSPC, cholesterol, and PEG-DMG in a molar ratio (e.g., 50:10:38.5:1.5) (Methods). Ethanol is the recommended solvent for initial dissolution. For siRNA or mRNA encapsulation, a microfluidic or ethanol injection method is used, followed by buffer exchange to physiological pH. The N/P ratio (nitrogen to phosphate) is optimized per application, commonly 6:1 for mRNA delivery (Results). Solutions should be prepared fresh and stored at ≤-20°C. For detailed protocols and troubleshooting, see the Dlin-MC3-DMA product page and this practical workflow guide (contrast: this article provides quantitative benchmarks and mechanistic detail in addition to stepwise protocols).

    Conclusion & Outlook

    Dlin-MC3-DMA is an established standard for LNP-mediated siRNA and mRNA delivery. Its pH-responsive, ionizable nature enables high potency and low toxicity, validated by both experimental and computational benchmarks. Ongoing research expands its applications to new tissues and disease models. Machine learning approaches are accelerating the optimization of Dlin-MC3-DMA-based LNPs for next-generation mRNA vaccines and cancer immunochemotherapy (Wang et al., 2022). For procurement and technical specifications, refer to APExBIO's Dlin-MC3-DMA A8791 kit.